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Abstract
Background: The antiretroviral therapy (ART) program of Cameroon recommends routine laboratory monitoring of
haematological toxicity if a regimen contains zidovudine (AZT) and of hepatotoxicity for NVP-containing regimens
on the 15th day after ART initiation. This study aimed to assess the relevance of this repeated laboratory measurements
considered to be precocious, inaccessible and unavailable in a resource limited setting.
Methods: A retrospective cohort of HIV-infected patients of age 15 years and above enrolled for first line ART at The
Regional Hospital of Nkongsamba in Cameroon. We monitored liver transaminases and blood cell indices after two
weeks of ART initiation for any significant change from baseline. Factors associated with abnormal changes were
examined using a multivariable logistic regression model with random effects.
Results: Enrolled were 154 patients of whom 105 (68.2%) were females. The mean ALAT (alanine aminotransferase)
level at baseline was 17.87 ± 20.48 U/L increasing to 19.25 ± 12.01 U/L at two weeks of follow-up (p = 0.53) while the
mean ASAT (aspartate aminotransferase) level increased from 17.32 ± 11.87 U/L at baseline to 21.02 ± 14.12 U/L at two
weeks of follow-up (p = 0.02). We observed a drop in the mean haemoglobin concentration from 10.86 ± 2.63 g/dL at
baseline to 10.36 ± 1.92 g/dL at the second week of follow-up (p = 0.02). The prevalence of elevated liver enzymes and
anaemia after two weeks of treatment were 7.5% and 39.2% respectively. Stavudine containing regimens were most
likely to induce hepatotoxicity [adjusted Odd Ratio (aOR) = 36.52, 95% CI: 1.44-924.38, p=0.029]. Baseline anaemia
(aOR=60.08, 95% CI: 13.36-270.20, p < 0.0001) and body weight ≥ 60kg (aOR=0.28, 95% CI: 0.09-0.83, p = 0.02) were
associated with anaemia at follow-up.
Conclusion: There was no significant rise in the mean level of transaminases and thus scheduling their routine
monitoring at the end of the second week could be skipped. Conversely, the drop in mean haemoglobin level had
little clinical importance but the high prevalence of anaemia after a fortnight on treatment suggests a targeted instead
of a routine monitoring; focusing on the high risk population with baseline anaemia and low body weight.
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Background
In 2012, 9.7 million people living with human immunodefi-
ciency virus (HIV) in low- and middle-income countries
received antiretroviral therapy (ART) [1]. Antiretroviral
therapy does not only prevent acquired immune deficiency
syndrome (AIDS)-related illness and death, it also has the
potential to significantly reduce the risk of HIV transmis-
sion and the spread of tuberculosis. From 1996 to 2012,
antiretroviral therapy averted 6.6 million AIDS-related
deaths worldwide, including 5.5 million deaths in low- and
middle-income countries [1]. However, ART is without ad-
verse effects that may have deleterious consequences on
the quality of care and treatment outcomes in the short or
long term. Zidovudine (AZT) is associated with a risk of
haematological toxicity, and measuring haemoglobin is
recommended before initiating ART, mainly among adults
and children with low body weight, low CD4 counts and
advanced HIV disease [2]. Nevirapine (NVP) increases the
risk of hepatotoxicity and monitoring hepatic enzymes is
recommended if feasible, especially for women with HIV
who have CD4 cell counts >250 cells/mm3 and individuals
with HIV who are coinfected with hepatitis-B virus (HBV)
or hepatitis-C virus (HCV) [2]. In order to determine and
minimize the incidence of drug toxicity associated with the
use of antiretroviral (ARV) medicines, The World Health
Organisation (WHO) recommends a symptom-directed
approach to laboratory monitoring of the safety and tox-
icity of ART regimens [2]. The periodicity of laboratory
monitoring and the key types of toxicities are determined
by various national ART programs. In Cameroon where
the HIV prevalence is 4.3% [3] and the ART coverage is
about 49.6% [4], the national guidelines in the light of
WHO 2010 guidelines recommend amongst others: the
maiden laboratory monitoring of haematological tox-
icity if a regimen contains AZT and hepatotoxicity for
NVP-containing regimens on the 15th day of ART initi-
ation [5].
The laboratory measurement of liver enzymes has very
low predictive value for NVP-containing regimens [2];
the incidence of ART-induced liver injury is low [6] and
might even be a very rare occurrence after a fortnight of
ART initiation; the cost of laboratory monitoring at the
end of the second week of starting ART regimens is not
subsidised and thus unlikely to be affordable to most
patients in Cameroon. The financial burden associated
with this early laboratory testing is likely to be a con-
tributory factor for the high rates of early attrition in
HIV care in Cameroon [7]. The increased work load
linked to this monitoring further stretches the already
constraint resources of the HIV program. Routine moni-
toring with multitest haematological and chemistry
panels is unlikely to be cost-effective [8]. As the validity,
feasibility and even the benefits of these precocious la-
boratory tests have therefore become uncertain; we
sought to determine their current relevance in a re-
source constraint setting. We assessed if there were any
significant pathological changes to the key haemato-
logical and biochemical markers from baseline to the
15th day of follow-up as well as the determinants of such
changes. We hoped that the findings of this study would
contribute in updating the country’s current guidelines
in line with the current WHO 2013 consolidated guide-
lines by selecting which laboratory tests to perform on
the basis of their utility at a given point in time.
Methods
Study site
The study was conducted at the HIV clinic of the Regional
Hospital of Nkongsamba, Moungo Division of the Littoral
Region of Cameroon. It is a second level reference public
health facility with a catchment area of over 321,295 in-
habitants [9]. The HIV clinic was established in 2005 and
offers HIV counselling and testing, ART and limited com-
munity outreach services to patients on ART. Routine
monitoring of ART for hepatic and haematological toxicity
at the 15th day of ART is common practice.
Ethical aspects
We used a database created in June 2012 as described
elsewhere in a study that was approved by the London
School of Hygiene and Tropical Medicine (LSHTM)
Ethics Committee [7]. Onsite permission to conduct the
study was provided by The Littoral Regional Office for
Public Health in Cameroon and The Director of The
Nkongsamba Regional Hospital. A written informed
consent from participants or legal representatives was
duly obtained where applicable.
Study design, participants and data collection
We carried out between February and April 2014, a
retrospective cohort of HIV-infected patients of age 15
years and above initiating first line ART and returning
two weeks later for their first follow-up visit between
2005 and 2012. From the available database we ab-
stracted the following information: socio-demographic
characteristics which were date of birth, gender, place of
residence, occupation, use of insecticide treated bed nets
(ITN), alcohol and tobacco consumption, education and
marital status. Clinical features such as baseline weight
and height, pregnancy status, disease and clinical stage
at presentation were also collected. Laboratory parame-
ters assessed at baseline and at the end of the two week
follow-up period included: haemoglobin level, mean red
cell volume (MCV), total leucocyte count, total platelet
count, liver transaminases which were alanine aminotrans-
ferase (ALAT) and aspartate aminotransferase (ASAT).
Baseline CD4 cell counts and fasting blood sugar levels
were also obtained. Treatment related variables such as
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the antiretroviral (ARV) regimen, drug side effects, flucon-
azole prophylaxis, cotrimoxazole prophylaxis, tuberculosis
treatment, the use of haematinics and traditional medica-
tion were noted. These data were entered into a form de-
signed using EpiInfo™ 7 software.
Laboratory analysis
Liver enzymes were assayed using the semi-automated bio-
chemistry analyser RAYTO RT-9900 (Hamburg, Germany)
using commercial reagents (Hospitex Diagnostics, Firenze,
Italy). Normal reference intervals for ALAT and ASAT ac-
cording to the laboratory for Cameroonian subjects were
(5–45 U/L) and (5–42 U/L), respectively. Full blood counts
were obtained using the URIT 3300 Automated Haematol-
ogy Analyser (URIT Medical Electronic Co Ltd, Guangxi,
China).
Data analysis
Data analyses were performed using Stata® 12.1(Stata-
Corp LP, TX77845, USA) and EpiInfo™ 7 (CDC, Atlanta,
USA). The data set was checked for logical inconsisten-
cies, illegal codes, omissions and improbabilities by tabu-
lating, summarising, describing and plotting variables.
Missing observations were excluded because they consti-
tuted a small random proportion.
Our main outcomes of interest included: liver enzyme
elevation (LEE) or transaminitis defined as ALAT >
45U/L and/or ASAT > 42U/L at the end of the study on
day 15 of follow-up on ART; low haemoglobin level (an-
aemia) defined as haemoglobin level < 10g/dL at day 15
after ART initiation. This haemoglobin cut-off point
of 10g/dL was based on the median value for the cohort
irrespective of gender and age. Leucopenia was consid-
ered as an absolute white blood cell count < 4.0 × 103
cells/μL while thrombocytopenia meant an absolute
platelet count < 1.5 × 105 cells/μL. The explanatory vari-
ables examined in our analyses included: age, gender,
body weight, marital and educational statuses, alcohol
intake, smoking, use of ITN, WHO clinical stage of HIV
disease, CD4 count, baseline haemoglobin and transami-
nases, pregnancy status, ARV regimen and other medica-
tions. No factor was considered as an a priori confounder
or effect modifier.
Summary statistics were presented as proportions for
categorical variables and as means (standard deviations)
or medians (IQR: Inter-quartile range) for continuous
variables. Paired t-test analyses were used to examine
the differences in means before and after ART. The
McNemar’s X2 test (if discordant pairs ≥20) or the Fisher’s
Exact test (if discordant pairs < 20) were used to compare
proportions from paired data. A multivariable logistic re-
gression model with random effects to account for corre-
lated data was used to pick up factors independently
associated with transaminitis or anaemia. Adjusted odd
ratios (aOR) and their 95% confidence intervals (95% CI)
were obtained. The p-values for hypotheses testing
were calculated from Wald or likelihood ratio tests
(LRT). A p-value <0.05 was considered significant.
Results
Characteristics of participants at baseline
The study enrolled patients initiating ART and returning
to the clinic two weeks later for their first routine la-
boratory monitoring. The results of 154 adults are re-
ported of whom 105 (68.2%) were females (Table 1).
Their median age was 40 years (IQR: 33–50.5) with a
median CD4 count of 204.5 cells/μl (IQR: 105–283.5).
Late clinical presentation (WHO stages III and IV) was
observed in 90 (65.7%) of cases with the commonest
conditions being the constitutional syndrome (48.9%),
lung disease (24.5%) and skin problems (6.7%). Over half
(52.6%) reported ever using alcohol, 60 (39%) said they
were using ITNs while just 19 (12.3%) declared they
were current smokers. Only eight (7.8%) had no formal
education and about half of them were married. The me-
dian ALAT level was 15U/L (IQR: 9.5-23) while the me-
dian ASAT level was 17U/L (IQR: 10–25). Moderate
elevation of liver enzymes (>3×ULN) was observed in
only 3 cases and severe elevation (>5×ULN) in none.
The red cell indices were characterised by a median
haemoglobin concentration of 10.6g/dl (IQR: 9.3-11.7)
and a median mean cell volume of 82fl (IQR: 75–86).
The median leucocyte and thrombocyte counts were re-
spectively 5.2 × 103 cells/ μl (IQR: 3.7-7.1) and 2.5 × 105
cells/μl (IQR: 2.0-3.0). With lamivudine (3TC) constantly
present in all the first line triple-combination antiretro-
viral regimens, zidovudine (AZT) completed the nucleo-
tide reverse transcriptase inhibitor (NRTI) backbone in
79 (53.4%) cases while nevirapine (NVP) in 88 (59.5%)
patients was the preferred non-nucleotide reverse tran-
scriptase inhibitor (NNRTI) option.
Comparison of laboratory measurements before and after
the second week of ART
The duration on ART was 14 days equivalent to the
study duration. Figure 1 shows that there was no evi-
dence that there was a true rise in the mean ALAT levels
from 17.87 ± 20.48 U/L at entry to 19.25 ± 12.01 U/L at
follow-up (p=0.53). The evidence that the increase in the
mean ASAT level from 17.32 ± 11.87 U/L to 21.02 ±
14.12 U/L was strong enough (p=0.02). ALAT and ASAT
were correlated (r=0.31, p=0.0001). There was a small
but significant fall in the mean haemoglobin concentra-
tion from 10.86 ± 2.63 g/dl to 10.36 ± 1.92 g/dl (p=0.02)
[Figure 2] accompanied by a significant increase in the
mean red cell volume from 79.62 ± 7.93 fl to 83.49 ± 9.13
fl (p=0.0004). While there was a very strong evidence
of a drop in the total white blood cell count of 1.37 ±
Bekolo et al. BMC Infectious Diseases 2014, 14:519 Page 3 of 10
http://www.biomedcentral.com/1471-2334/14/519
Table 1 Baseline characteristics of study participants
Characteristics Number (%) Characteristics Number (%)
Gender Absolute leucocyte count (/μl)
Female 105 (68.2)
Male 49 (31.8) <4000 36 (27.1)
Total 154 (100) ≥4000 97 (72.9)
Total 133 (100)
Age group (years) Absolute platelet count (/μl)
<30 19 (12.5)
30-49 93 (61.2) <150000 19 (13.9)
≥50 40 (26.3) ≥150000 118 (86.1)
Total 152 (100) Total 137 (100)
Marital status Fasting blood sugar (mg/dl)
Single 47 (32.2)
Married 73 (50.0) <126 130 (94.2)
Divorced 4 (2.7) ≥126 8 (5.8)
Widowed 22 (15.1) Total 138 (100)
Total 146 (100)
Education level NRTI-based regimen
None 8 (7.8) AZT-based 79 (53.4)
Primary 33 (32.4) D4T-based 2 (1.3)
Secondary 57 (55.9) ABC-based 1 (0.7)
Higher 4 (3.9) TDF-based 66 (44.6)
Total 102 (100) Total 148 (100)
Alcohol use NNRTI-based regimen
No 73 (47.4)
Yes 81 (52.6) NVP-based 88 (59.5)
Total 154 (100) EFV-based 60 (40.5)
Total 148 (100)
Smoking Other medications
No 135 (87.7) Tuberculosis 5 (3.25)
Yes 19 (12.3) Haematinics 76 (49)
Total 154 (100) Cotrimoxazole 133 (86.4)
Fluconazole 7 (4.5)
Traditional medicines 1 (0.7)
Pregnancy CD4 count (cells/μl)
No 144 (93.5) <350 134 (93.1)
Yes 10 (6.5) ≥350 10 (6.9)
Total 154 (100) Total 144 (100)
ITN use ALAT (U/L)
No 94 (61.0) <45 136 (94.4)
Yes 60 (39.0) ≥45 8 (5.6)
Total 154 (100) Total 144 (100)
WHO clinical stage ASAT (U/L)
I 26 (19.0) <42 132 (91.7)
II 21 (15.3) ≥42 12 (8.3)
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3.62 × 103 cells/ μl, the decrease in the total platelet
count of 0.03 ± 1.18 × 105 cells/ μl was not significant
(Table 2).
Prevalence and determinants of transaminitis and
cytopenia after ART initiation
Elevated transaminases or transaminitis was observed in
8.3% of the patients before starting ART and in 7.5% of
them after two weeks of treatment with no significant
difference between the proportions (Figure 3). Moderate
elevation (>3×ULN) and severe elevation (>5×ULN) were
recorded in none of the cases. The frequency of anaemia
before treatment was 32.4% and rose significantly to
39.2% at the end week 2 of treatment (p=0.02). The
prevalence of leucopenia at entry was 27.1%, increasing
to 32.2% at follow-up. Though drastic, the fall in the oc-
currence of thrombocytopenia from baseline (13.9%) to
follow-up (5.8%) was probably a chance finding (p=0.3).
Fasting blood sugar and ALAT were correlated
(r=0.34, p < 0.0001).
There was some evidence that stavudine containing
regimens were most likely to induce hepatotoxicity com-
pared with other NRTI-based regimens (aOR=36.52,
95% CI: 1.44-924.38, p=0.029) as Table 3 depicts.
In univariable analysis, baseline anaemia, tenofovir con-
taining regimens, marital status, low body weight, use of
haematinics and ITNs were associated with anaemia. After
correcting for other covariates in a multivariable model,
patients with anaemia at presentation were very likely to
remain anaemic after two weeks of therapy (aOR=60.08,
95% CI: 13.36-270.20, p < 0.0001). A body weight of 60kg
and above was associated with a 72% reduction in the risk
of anaemia at day 15 of ART (aOR=0.28, 95% CI: 0.09-
0.83, p=0.02). Subjects who reported using an ITN were
associated with a 4.6-fold increase in the odds of develop-
ing anaemia (aOR=4.60, 95% CI: 1.35-15.71, p=0.015).
Discussion
This study has demonstrated neither a statistically nor a
clinically significant liver enzyme elevation (LEE) after
Table 1 Baseline characteristics of study participants (Continued)
III 83 (60.6) Total 144 (100)
IV 7 (5.1)
Total 137 (100)
Weight (kg) Haemoglobin (g/dl)
<60 62 (43.7) <10 47 (32.4)
≥60 80 (56.3) ≥10 98 (67.6)
Total 142 (100) Total 145 (100)
ALAT = alanine aminotransferase, ASAT = aspartate aminotransferase, ITN = insecticide treated nets, NRTI = nucleotide reverse transcriptase inhibitor, NNRTI = non-












Initial ALAT Final ALAT
Initial ASAT Final ASAT
Figure 1 Evolution of liver enzymes before and after two weeks of antiretroviral therapy initiation.
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two weeks of ART initiation. Though there was a statis-
tically significant rise in the frequency of anaemia after a
fortnight of receiving ART, the presence of anaemia
prior to ART initiation was the key determinant.
The prevalence of liver enzyme elevation after two
weeks of ART was 7.5% in our cohort all of which were
mild and asymptomatic elevations (<3×ULN). The find-
ings are consistent with the reported prevalence rates of
1% to 10% in developed countries [10-13] and of <1% to
7% across cohorts from developing countries [14-17].
The variability in the frequency of ART-induced liver in-
jury has been attributed to differences in the choice of
ARV regimen used, comorbid conditions, concomitant
or alternative therapies, host genetics, available labora-
tory monitoring technology. The small sample size, the
laboratory reference intervals or cut-off points and the
short duration of exposure to ART in our cohort may
further explain the variability in the occurrence of LEE.
Given that the duration on ART was constant and that
the difference between baseline and follow-up LEE was in-
significant, the incidence of LEE that can be attributable
to ART is also likely to be negligible. The effect of HIV in-
fection on liver enzymes might wholly be responsible for
the observed LEE. Similarly, the before and after ART
mean difference in liver enzymes may have statistical im-
portance in this study but clinically, the mean transamin-
ase levels are just about a half of their upper limits of
normal. This therefore means that a two-week course of
ART has little or no clinical impact on liver enzymes.
Moreover, the stavudine-containing regimen that has been
isolated in our study as the single most important con-
tributor of LEE has completely been phased out in
Cameroon. Consequently, monitoring liver enzymes for
drug toxicity at the end of the second week of ART may
not be necessary. The implication of this finding would be
economical: on one hand, patients who pay out of their
pockets for these tests would now have more money to be
diverted to other treatment related expenses like transpor-
tation and feeding; on the other hand, the country pro-
gram would equally stand to benefit as some of the
already constraint human and material resources will be








Initial haemoglobin Final haemoglobin
Figure 2 Evolution of haemoglobin level before and after two weeks of antiretroviral therapy initiation.











ALAT (U/L) 17.87 (20.48) 19.25 (12.01) −1.37 (23.10) −5.73-2.99 0.53
ASAT (U/L) 17.32 (11.87) 21.02 (14.12) −3.70 (16.61) −6.84- -0.56 0.02
Haemoglobin (g/dl) 10.86 (2.63) 10.36 (1.92) 0.50 (2.29) 0.08-0.92 0.02
Mean cell volume (fl) 79.62 (7.93) 83.49 (9.13) −3.86 (8.98) −5.95- -1.78 0.0004
Absolute leucocyte count (103/μl) 6.21 (3.44) 4.84 (1.76) 1.37 (3.62) 0.66-2.09 0.0002
Absolute platelet count (105/μl) 2.72 (1.07) 2.69 (1.14) 0.03 (1.18) −0.20- 0.25 0.82
ART = antiretroviral therapy, ALAT = alanine aminotransferase, ASAT = aspartate aminotransferase, CI = confidence interval.
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to justify the cost-effectiveness of such a recommendation
in perspective.
The prevalence of anaemia after two weeks of ART was
39.2%. This rate is higher than the rates of 3% to 12% in
studies from Nigeria, Cote d’Ivoire, Haiti and India though
the latter were related to long-term zidovudine-based
therapies [14,15,18-20]. The rate is however lower than
either the 76% observed at the 6th week of using a winnie-
cure antiretroviral drug in a Nigerian cohort [21] or the
46% reported in a Ghanaian population receiving ART for
at least 3 months [22]. We observed a 0.5g/dl drop in
mean haemoglobin from baseline to the end of second
week of follow-up. A similar decrease of 0.5g/dl in the first
three months of using AZT-based regimens has been ob-
served in large cohorts across countries in sub-Saharan
Africa, Asia-Pacific, and Central and South America [23]
but Mgogwe et al. had reported a decrease of up to 1.3g/dl
during six months of ART in Tanzania [24]. Conversely, a
rise in mean haemoglobin levels has been experienced in
patients receiving non-AZT regimens [23] and after a long
term use of successful treatment combinations with or
without AZT [21,25,26].
The 0.5g/dl drop in the mean haemoglobin level was
statistically significant but may have little clinical im-
portance after two weeks of treatment when the mean
haemoglobin had remained satisfactorily above 10g/dl.
Unlike liver enzymes, the significant rise of about 6.8%
in the prevalence of anaemia after a fixed two-week
period from baseline might indicate a true increase in
the incidence of anaemia that can be attributed to ART
assuming that other predictors of anaemia remained un-
changed during this very short exposure time. The high
prevalence of anaemia at baseline and during follow-up
coupled with a significant fall in the total leucocyte
count in this cohort, and the fact that anaemia is known
to have been associated with a 2.5-fold increase in the
risk of mortality in the same but a larger cohort [7],
means that early monitoring of haematological indices
for ARV drug-induced myelosuppression is justifiable.
Baseline anaemia was frequent and was a major pre-
dictor of anaemia at follow-up in this study and several
others [2,8,23,26]. Unlike other cohorts, our study dur-
ation of 15 days was too short to allow for a complete
red blood cell turnover of 120 days, therefore the per-
sistence of anaemia was inevitable. Late presentation
was prevalent (65.7%) in our study population and is
likely to be responsible for the high prevalence of anaemia.
This overwhelming contribution of baseline anaemia at
initiation of ART suggests that a targeted monitoring of
ART for haematological toxicity could be an alternative
for the on-going routine monitoring.
Low body weight (LBW) which is indicative of low
body mass index (BMI) was associated with more than a
3.5-fold increase in the odds of anaemia after initiating
ART. LBW is a surrogate marker of advanced HIV infec-
tion or poor nutritional status characterised by depleted
iron and protein stores required for the production of
haemoglobin.
Use of ITN is well known to reduce the impact of mal-
aria and anaemia in developing countries [27]. Paradox-
ically, in this study users of ITNs had a higher risk of
anaemia than non-users. We could neither ascertain the
effectiveness, nor ownership nor the duration of the sup-



























Biochemical and haematological abnormalities
Before ART After two weeks on ART
p=0.4 p=0.2 p=0.02 p=0.12 p=0.30
Figure 3 Prevalence of liver enzyme elevation and cytopenia at baseline and at follow-up.
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case. An unknown factor distal or proximal to ITN such
as socio-economic status or geographical location of
users may be responsible for this strong association be-
tween ITN use and risk of anaemia.
Though tenofovir-containing regimens and the use of
haematinics (iron ± folate ± vitamin B12) were very
strong determinants of anaemia in univariate analysis,
they were correctly ruled out after adjusting for other
factors and for correlation in data. This is due to the fact
that patients presenting with anaemia at baseline were
given haematinics and in order to avoid worsening of
anaemia they were more likely to receive non-AZT regi-
mens especially TDF because D4T was being phased-
out. This selection bias was responsible for the apparent
association. It is has now been demonstrated that base-
line severe anaemia should not preclude use of zidovu-
dine in antiretroviral-eligible patients in resource-limited
settings [26].
Our study had some draw backs. The sample size was
small and made up of patients returning voluntarily to
the clinic and able to afford for the laboratory investiga-
tions at the 15th day of starting ART. All patients
Table 3 Predictors of early liver enzyme elevation and anaemia after two weeks of antiretroviral therapy
Characteristics Crude odd ratios
(95% Confidence Interval)
p-value Adjusted odd ratios
(95% Confidence Interval)
p-value
Early liver enzyme elevation
NRTI-based regimens
AZT-based 1 1
D4T-based 18.3 (0.91-370.28) 0.058 36.52 (1.44-924.38) 0.029
ABC-based 1 1
TDF-based 1.83 (0.42-8.07) 0.423 3.43 (0.61-19.21) 0.160
Fasting blood sugar (mg/dl)
<126 1 1




<10 25.6 (8.61-76.17) <0.0001 60.08 (13.36-270.20) <0.0001
Body weight (kg)
<60 1 1
≥60 0.32 (0.12-0.88) 0.027 0.28 (0.09-0.83) 0.022
Use of ITN
No 1 1




ABC-based 1 1 0.252
TDF-based 3.38 (1.56-7.32) 0.002 2.01 (0.61-6.64)
Use of haematinics
No 1 1
Yes 3.74 (1.75-8.00) 0.001 1.06 (0.32-3.49) 0.921
Marital status
Single 1 1
Married 0.43 (0.18-0.99) 0.049 0.54 (0.14-2.01) 0.357
Divorced 1 1
Widowed 0.47 (0.15-1.53) 0.212 0.81 (0.15-4.42) 0.804
ITN = insecticide treated nets, NRTI = nucleotide reverse transcriptase inhibitor, NNRTI = non-nucleotide reverse transcriptase inhibitor, ABC = abacavir, D4T = stavudine,
AZT = zidovudine, TDF = tenofovir, EFV = efavirenz, NVP = nevirapine.
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receiving ART at the clinic are usually informed of the
necessity for the first visit which also has a clinical com-
ponent. This suggests that persons with low socio-
economic status or living far off from the clinic might
have been excluded. There is no reason however to be-
lieve that the subgroup that did not have a laboratory
monitoring at day-15 of ART (but had at least a clinical
monitoring) must have experienced a different toxicity
profile because drug toxicity is essentially a biological
phenomenon. The study’s retrospective design made it
liable to incompleteness of information collected. For
example, we could not obtain data about co-infection
with the hepatitis viruses B and C which are prevalent in
this setting.
Conclusion
In conclusion, at the end of the second week of ART ini-
tiation, there has been no significant rise in mean liver
enzymes and thus scheduling their routine monitoring
at that point in time could be skipped. Fortunately, the
ART program has also scheduled their monitoring
where appropriate at the 30th, 60th, 90th day and so on
[5]. Conversely, the drop in mean haemoglobin level
during the second week of ART has had little clinical
importance but the high prevalence of anaemia warrants
a targeted monitoring as an alternative to routine labora-
tory monitoring particularly for the high risk population
with baseline anaemia and low body weight.
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